SOURCE: OmniComm Systems, Inc.

July 19, 2005 02:00 ET

CINRG Awards OmniComm Additional Clinical Trials

FORT LAUDERDALE, FL -- (MARKET WIRE) -- July 19, 2005 -- OmniComm Systems, Inc. (OTC BB: OMCM), one of the fastest growing companies in the EDC marketplace, is pleased to announce that CINRG, the Cooperative International Neuromuscular Research Group, has once again chosen OmniComm's TrialMaster® EDC solution to support two critical upcoming Phase III studies. CINRG is the clinical research arm of the Duchenne Muscular Dystrophy Research Center ("DMDRC"), and houses its Coordinating Center at the Children's National Medical Center. CINRG has been a client of OmniComm since 2001 and has used TrialMaster in three separate Muscular Dystrophy Association sponsored clinical trials. OmniComm has developed custom software that allows CINRG to dynamically manage, monitor and archive data collected from muscle strength testing devices.

By leveraging TrialMaster's flexible solutions across Phase II and Phase III clinical trials, CINRG can expedite the collection and management of high quality trial data, and ultimately reduce time in bringing needed drugs and therapies to individuals with DMD.

"We are pleased to be partnering with OmniComm, a company that has demonstrated its experience and ability in delivering comprehensive clinical data solutions on a global basis. Use of the TrialMaster system has allowed us to build a robust data management and safety review process, and we are confident that TrialMaster will continue to enhance our efficiency in the drug discovery process," said Erik Henricson, MPH, CINRG researcher and the coordinator of the network.

"OmniComm is pleased to be participating in the only large-scale muscular dystrophy clinical research effort in the world. Our relationship with CINRG represents an affirmation of the excellence of TrialMaster and of our company's commitment to serving our clients," said Cornelis Wit, CEO at OmniComm. "CINRG's adoption of, and continued use of TrialMaster technology also validates the growing trend in the industry that healthcare institutions are seeking efficient, secure and flexible solutions for clinical data management to make the most of the considerable benefits that this technology offers."

CINRG is a leader in the field of the advancement of knowledge and development of effective treatments for people with Duchenne Muscular Dystrophy and related disorders globally. CINRG provides an environment conducive to the effective research of these disorders by providing access to collaborative research and access to state-of-the-art technologies.

About OmniComm Systems, Inc.

OmniComm Systems, Inc. (www.omnicomm.com) is one of the fastest growing companies in the EDC market place targeting its product TrialMaster® to the pharmaceutical, medical device and biotechnology companies as well as CROs. OmniComm's growing base of satisfied customers is a direct result of OmniComm's employee's commitment to on-time, quality and within budget performance.

The TrialMaster (www.trialmaster.com) system, the core product of OmniComm, provides trial sponsors with a 21 CRF Part 11 compliant Internet-based data and trial management solution that greatly increases the efficiency, security and integrity of clinical research data and thus significantly reduces the time and expense involved in conducting clinical studies.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

  • Contact:
    Rusty Beardsley
    Sr. VP Marketing and Sales
    OmniComm Systems, Inc.
    215-542-8828
    Email Contact